Search

Your search keyword '"Blank, Christian"' showing total 32 results

Search Constraints

Start Over You searched for: Author "Blank, Christian" Remove constraint Author: "Blank, Christian" Publisher elsevier science ltd Remove constraint Publisher: elsevier science ltd
32 results on '"Blank, Christian"'

Search Results

1. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy.

2. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.

3. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

4. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

5. The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.

6. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.

7. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

8. Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies.

9. Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery.

10. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma.

11. Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry.

12. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.

13. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.

14. Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study.

15. Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

16. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.

17. Adjuvant treatment for melanoma in clinical practice - Trial versus reality.

18. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

19. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.

20. Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!

21. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.

22. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

23. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

24. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

25. An open-label, multicentre safety study of vemurafenib in patients with BRAF V600 -mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

26. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.

27. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

28. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

29. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.

30. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

31. Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.

32. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

Catalog

Books, media, physical & digital resources